SynthesisRheumatology (Oxford, England)2025
The role of prokinetics in managing gastrointestinal involvement in SSc: a systematic literature review.
Synthesis in Rheumatology (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systemic sclerosis and small bowel involvement: A systematic review of diagnostic approaches and current evidence.Seminars in arthritis and rheumatism · 2026Pooled it
- Proton pump inhibitor use and long-term outcomes in SSc: a real-life analysis from the EUSTAR database.Rheumatology (Oxford, England) · 2026Article
- Gastrointestinal Disorders in Scleroderma.Gastroenterology · 2026Review
- Gastrointestinal involvement in systemic sclerosis: A spotlight on small bowel involvement, complications and management.Best practice & research. Clinical rheumatology · 2026Review
- PPI-Refractory GERD in Systemic Sclerosis Is Driven by Distinct Esophageal and Gastric Motility Abnormalities.medRxiv : the preprint server for health sciences · 2026Article
- Delayed gastric emptying identifies a high-risk clinical subgroup in patients with systemic sclerosis.Rheumatology (Oxford, England) · 2026Article
- Effects of proton pump inhibitors plus gastroprokinetic agents on laryngopharyngeal reflux disease and factors influencing prognosis.American journal of translational research · 2026Article
- Expert recommendations for the management of refractory gastroesophageal reflux disease in systemic sclerosis: A report from the World Scleroderma Foundation (WSF) Gastrointestinal "Ad hoc committee".Journal of scleroderma and related disorders · 2026Article
- Expert recommendations for the management of fecal incontinence in systemic sclerosis: A report from the World Scleroderma Foundation (WSF) Gastrointestinal "Ad hoc committee".Journal of scleroderma and related disorders · 2026Article
- Eradication of Small Intestinal Bacterial Overgrowth in Systemic Sclerosis: Current Treatment and Perspectives-A Narrative Review.Biomedicines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectivesGastrointestinal involvement (GI) in SSc is frequent and heterogeneous, manifesting with different degrees of dysmotility. This systematic literature review aimed to summarize evidence on prokinetics for treating SSc-related GI dysmotility.
methodsStudies investigating the effects of prokinetic agents on GI function and/or GI symptoms in patients with SSc were systematically identified on PubMed and Embase. A qualitative data synthesis was conducted, given the (anticipated) wide heterogeneity in study designs, interventions and outcomes.
resultsTwenty-one studies evaluating the effects of prokinetics in patients with SSc were included. Thirteen studies focused on GI motility using objective tests, eight assessed clinical responses, and six evaluated both. Cisapride (n = 5 studies), metoclopramide (n = 7 studies), octreotide (n = 4 studies) and prucalopride (n = 1 study) were among the most studied prokinetics, with varying effects on different GI anatomical regions. While metoclopramide consistently improved overall GI motility, other prokinetics provided selective benefits; cisapride improved gastric emptying and colonic motility, but not oesophageal motility, and octreotide improved small bowel motility but delayed gastric emptying. Regarding symptomatic improvement, only prucalopride was evaluated using a validated patient questionnaire, showing improvement in both upper and lower GI symptoms.
conclusionProkinetic drugs may improve GI motility and symptoms in patients with SSc. There is an unmet need for future well-designed studies to refine patient stratification and optimize treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.